Replies to post #108425 on Biotech Values

[DFRAI]

Dew et al

Is this active development - FOB - Orencia? same m187 that was dropped with Novartis?

Other than scientific acknowledgement - are they planning to take it further? thanks.

[DewDiligence]

Orencia factoids:

In 3Q10, Orencia had annualized sales of $740M, of which $550M was in the US. Orencia was approved by the FDA in Dec 2005. The annual growth rate is in the low teens.

Source: http://www.bms.com/news/press_releases/pages/default.aspx?RSSLink=http://www.businesswire.com/news/bms/20101026005606/en&t=634080643559098153

[pcrutch]

When do you think MNTA might be looking to challenge this?

Relevant Orencia patent info
"The Company has a series of patents covering abatacept and its method of use. A patent term extension has been granted for one of the U.S. composition of matter patents that expires in 2015, extending the term of the patent to 2019. In the majority of the EU countries, the Company has a patent covering abatacept that expires in 2012. Data exclusivity in the EU expires in 2017. "